Summary of "e-PICU - Session 12 Pediatric Intensive Care"

Summary of “e-PICU - Session 12 Pediatric Intensive Care”

This session focused on hospital healthcare-associated infections (HAIs) in pediatric intensive care, with a detailed discussion on antimicrobial resistance, antibiotic stewardship, and infection management in critically ill children. The session was led by Dr. Bal Mukund, an infectious disease specialist, and moderated by senior experts Dr. Punit and Dr. Shalu Gupta.

Main Ideas and Concepts

Terminology and Importance of HAIs
- The term “hospital-associated infections” (HAI) is preferred over “hospital-acquired infections” to avoid blame connotation.
- HAIs in pediatric ICUs are complex due to multidrug-resistant organisms (MDROs).
Case-Based Learning
- Several clinical cases illustrated common infections in PICU, including:
  - Urinary tract infections (UTI) with ESBL-producing E. coli.
  - Enteric fever with multidrug resistance, especially from neighboring countries.
  - Ventilator-associated pneumonia (VAP) and its diagnostic criteria.
  - Neonatal meningitis complicated by resistant organisms.
  - Infections with difficult-to-treat organisms like Stenotrophomonas and carbapenem-resistant Acinetobacter baumannii (CRAB).
Antimicrobial Resistance Mechanisms
- ESBL (Extended-Spectrum Beta-Lactamase) definitions and importance.
- Carbapenemases classification (Ambler classes A, B, D), with emphasis on NDM (New Delhi Metallo-beta-lactamase) as a major resistance enzyme in India.
- Regional variation in resistance patterns, highlighting the need to use local antibiograms rather than relying solely on Western guidelines.
- Importance of understanding MIC (Minimum Inhibitory Concentration) breakpoints and their yearly updates.
Antibiotic Selection and Stewardship
- Carbapenems remain the drug of choice for many ESBL infections but resistance is rising.
- Piperacillin-tazobactam (pip-tazo) is recommended only for urinary tract infections, not for high bacterial burden infections due to the inoculum effect.
- Colistin (polymyxins) should not be used as monotherapy; combination therapy with sulbactam-doripenem or imipenem is preferred for CRAB.
- Newer antibiotic combinations such as ceftazidime-avibactam, cefiderocol, and sulbactam-doripenem are emerging but often costly and not widely available.
- Aminoglycosides have limited role in bloodstream infections but can be synergistic in carbapenem-resistant E. coli.
Diagnostic Advances
- Rapid molecular tests like Carba NP, Carba Expert PCR, and BioFire BCID panel can detect resistance genes quickly, aiding timely antibiotic choice.
- Limitations of PCR-based respiratory panels include detection of colonizers and multiple organisms, requiring clinical correlation.
- MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) offers rapid organism identification but no susceptibility data.
Special Topics
- Fungal infections: diagnostic challenges, use of biomarkers (BDG, galactomannan), and resistance patterns in Candida species.
- MRSA and Staphylococcus aureus infections: importance of understanding phenomena like antigenic drift and skip phenomenon affecting culture results.
- Discussion on prolonged infusion of meropenem in certain resistant infections.
- Emphasis on prevention strategies including hand hygiene and minimizing invasive devices.
Take-Home Messages
- Prevention is better than cure: strict infection control measures are critical.
- Antibiotic choice must be guided by local resistance data, not just international guidelines.
- Judicious use of antibiotics is essential to combat resistance.
- Continuous education and awareness about evolving resistance patterns and new therapies are vital.

Detailed Methodologies / Instructions

Diagnosis of Ventilator-Associated Pneumonia (VAP)

Diagnosis requires:
- Clinical deterioration
- Radiological worsening
- Positive culture or quantitative aspirate
Avoid diagnosing VAP within 48 hours of ventilation or based on fever alone.
Do not rely on endotracheal (ET) aspirate culture alone due to colonization.

Antibiotic Selection for ESBL and Carbapenem-Resistant Organisms

If ESBL detected (e.g., resistance to ceftriaxone), use carbapenems for serious infections.
For carbapenem-resistant organisms:
- Identify carbapenemase type (NDM, OXA-48, KPC) using molecular tests.
- Use ceftazidime-avibactam or sulbactam-doripenem combinations based on resistance profile.
- Add aminoglycosides for synergy in certain E. coli infections.
- Avoid piperacillin-tazobactam outside urinary tract infections.
- Use combination therapy for CRAB and Stenotrophomonas infections.

Management of Enteric Fever

Avoid Widal test; rely on culture methods.
Use high-dose dexamethasone in severe cases with CNS involvement or shock.
Consider regional resistance patterns, especially in patients with travel history.

Handling Multidrug-Resistant Pseudomonas

Recognize DTR (Difficult-to-Treat Resistant) Pseudomonas.
Use newer beta-lactam/beta-lactamase inhibitor combinations like ceftolozane-tazobactam.
Preserve carbapenems when possible.

Fungal Infection Diagnostics

Use BAL galactomannan for sensitivity; serum galactomannan for specificity.
BDG test has limited pediatric utility and may be misleading in endemic fungal infections like paracoccidioidomycosis.
Therapeutic drug monitoring recommended for antifungals like voriconazole.

Infection Control Recommendations

Rigorous hand hygiene.
Early removal of invasive devices.
Rational antibiotic prescribing starting from primary care level.

Speakers / Sources Featured

Dr. Bal Mukund – Infectious disease specialist, lead speaker.
Dr. Manindra Dali – Program organizer and faculty.
Dr. Shalu Gupta – Moderator, Director Professor at LHMC Kalawati Hospital.
Dr. Punit (Pune) – Senior mentor from DMC Ludhiana, moderator.
Dr. Ragnatam – Faculty member (briefly mentioned).
Dr. Maninda – Faculty and program designer.
Dr. Balaji – Microbiologist from CNC, source of regional resistance data (referenced).
Dr. AJ, Dr. DH, Dr. Sham, Dr. Shashil – Program team and support.

Overall, this session was a comprehensive, case-based exploration of pediatric ICU infections with a strong emphasis on antimicrobial resistance, tailored antibiotic therapy based on local epidemiology, and the critical role of infection prevention.